Triple

T22690299
Position Surface form Disambiguated ID Type / Status
Subject CDK4 E561032 entity
Predicate regulatedBy P86 FINISHED
Object CDKN2D (p19INK4D) NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CDKN2D (p19INK4D) | Statement: [CDK4, regulatedBy, CDKN2D (p19INK4D)]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: CDKN2D (p19INK4D)
Context triple: [CDK4, regulatedBy, CDKN2D (p19INK4D)]
  • A. CDKN2C (p18INK4C)
    CDKN2C (p18INK4C) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • B. CDKN2B (p15INK4B)
    CDKN2B (p15INK4B) is a cyclin-dependent kinase inhibitor tumor suppressor protein that controls cell cycle progression by inhibiting CDK4/6 activity.
  • C. CDKN2A (p16INK4A)
    CDKN2A (p16INK4A) is a tumor suppressor gene encoding a cyclin-dependent kinase inhibitor that controls cell cycle progression and is frequently inactivated in human cancers.
  • D. CDK4
    CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
  • E. cyclin D2
    Cyclin D2 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases involved in cell proliferation.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: CDKN2D (p19INK4D)
Target entity description: CDKN2D (p19INK4D) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • A. CDKN2C (p18INK4C)
    CDKN2C (p18INK4C) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
  • B. CDKN2B (p15INK4B)
    CDKN2B (p15INK4B) is a cyclin-dependent kinase inhibitor tumor suppressor protein that controls cell cycle progression by inhibiting CDK4/6 activity.
  • C. CDKN2A (p16INK4A)
    CDKN2A (p16INK4A) is a tumor suppressor gene encoding a cyclin-dependent kinase inhibitor that controls cell cycle progression and is frequently inactivated in human cancers.
  • D. CDK4
    CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
  • E. cyclin D2
    Cyclin D2 is a regulatory protein that controls progression through the G1 phase of the cell cycle by activating cyclin-dependent kinases involved in cell proliferation.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454d71b48190a1f80af9f82b6fcf completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1789a1fd08190bce5fa0babe695d3 completed April 29, 2026, 3:18 a.m.
Created at: April 17, 2026, 3:13 p.m.